Anti-Human NOTCH1 Recombinant Antibody (Brontictuzumab) (CAT#: TAB-H11)

Figure 1 The Notch1 inhibitor brontictuzumab led to significant tumor growth inhibition exclusively in the ACCX9 patient-derived xenograft model harboring a NOTCH1 activating mutation (I1680N).

Mice were treated with brontictuzumab by intraperitoneal injection at 10 mg/kg once every 2 weeks for two total doses, and mean tumor volume was assessed

Ferrarotto, R., Mitani, Y., Diao, L., Guijarro, I., Wang, J., Zweidler-McKay, P., ... & Kapoun, A. M. (2017). Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to Notch1 inhibitors. Journal of Clinical Oncology, 35(3), 352.

Figure 2 Brontictuzumab induces significant tumor growth inhibition exclusively in the ACCX9 patient-derived xenograft model harboring a NOTCH1 activating mutation (I1680N).

Ferrarotto, R., Mitani, Y., Diao, L., Guijarro, I., Wang, J., Zweidler-McKay, P., ... & Kapoun, A. M. (2017). Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to Notch1 inhibitors. Journal of Clinical Oncology, 35(3), 352.

Figure 1 Anti-Human NOTCH1 Recombinant Antibody in SDS-PAGE

Lane M: Protein Marker Lane 1: Non-Reducing (2.0 μg) Lane 2: Reducing (2.0 μg)